Does Phytoceramides Skin Hydration Randomized Trial work?

Updated August 2026

Quick Answer

Phytoceramides Skin Hydration Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: This increase has significantly impacted the costs associated with medical treatment and resulted in additional expenses for patients and their families [].

Key Takeaways

  • 01This increase has significantly impacted the costs associated with medical treatment and resulted in additional expenses for patients and their families []. [Ali Sibel (2024)]
  • 027 8 10 11 Genetic factors contribute to the complexity of the pathophysiology of AD, as certain polymorphisms are associated with changes in skin barrier function and immune responses. [Ali Sibel (2024)]
  • 03For instance, mutations in the filaggrin gene have been linked to a higher risk of developing AD [,]. [Ali Sibel (2024)]
  • 041 1 2 3 4 4 1 Atopic dermatitis (AD) is a chronic inflammatory skin disease that mainly affects children, with a prevalence of 10 to 20% []. [Ali Sibel (2024)]
The current Migaku evidence database contains 2 reusable source documents for Phytoceramides Skin Hydration Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - This increase has significantly impacted the costs associated with medical treatment and resulted in additional expenses for patients and their families []. [Ali Sibel (2024); evidence level 3] - 7 8 10 11 Genetic factors contribute to the complexity of the pathophysiology of AD, as certain polymorphisms are associated with changes in skin barrier function and immune responses. [Ali Sibel (2024); evidence level 3] - For instance, mutations in the filaggrin gene have been linked to a higher risk of developing AD [,]. [Ali Sibel (2024); evidence level 3] - 1 1 2 3 4 4 1 Atopic dermatitis (AD) is a chronic inflammatory skin disease that mainly affects children, with a prevalence of 10 to 20% []. [Ali Sibel (2024); evidence level 3] - AD is characterized by elevated levels of skin eosinophils, neutrophils, and mast cells; lymphocyte infiltration; and increased immunoglobulin (Ig) E levels []. [Pareek Ashutosh (2024); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis
  2. Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives